Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
ObjectiveThe treatment with 177Lutetium PSMA (177Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC) has recently been approved by the FDA and EMA. Since treatment success is highly variable between patients, the prediction of treatment response and identification of sh...
| Հիմնական հեղինակներ: | , , , , , , , , |
|---|---|
| Ձևաչափ: | Հոդված |
| Լեզու: | English |
| Հրապարակվել է: |
Frontiers Media S.A.
2023-09-01
|
| Շարք: | Frontiers in Nuclear Medicine |
| Խորագրեր: | |
| Առցանց հասանելիություն: | https://www.frontiersin.org/articles/10.3389/fnume.2023.1234853/full |